Takeda reports additional data from Nesina CV outcomes trial

Share this article:

Takeda has released new data from its cardiovascular safety outcomes trial—EXAMINE—for DPP-4 inhibitor and diabetes treatment Nesina (alogliptin). The study investigated alogliptin's effect on rates of cardiovascular mortality and hospitalization for heart failure in patients with recent acute coronary syndrome.

The company said that its drug “demonstrated no effect on rates of CV mortality,” compared to placebo, and “there was also no increase in sudden cardiac death with alogliptin.”

The trial's principal investigator and abstract author, William B. White, MD, said in a statement, "Cardiovascular events are very common in patients with Type 2 diabetes, so it is important that diabetes treatments adequately manage glucose levels in these patients without adversely affecting cardiovascular outcomes, such as hospitalized heart failure and cardiac death. Based on data presented, alogliptin showed no difference from placebo on rates of cardiovascular mortality and hospitalized heart failure in this high-risk population of patients with Type 2 diabetes." 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.